VISCHER advised LASCCO SA on all legal issues related to the license agreement. LASCCO SA, a biomedical-technology company, and Abionic SA, a nanotechnology company, both based...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
You must be a Standard 1 Year member to access this content.
VISCHER acted as legal advisor to LimmaTech Biologics in the transaction. LimmaTech Biologics AG closed a USD 37m (CHF 33m) Series A financing round co-led by Adjuvant...
You must be a Standard 1 Year member to access this content.
VISCHER advised Medartis on the deal. Medartis (SIX: MED), a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private...
You must be a Standard 1 Year member to access this content.
Vischer advised Anokion in this transaction, while Walder Wyss advised Pfizer. Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune...
You must be a Standard 1 Year member to access this content.
Lenz & Staehelin advised co-lead investors Samsara Biocapital and Lightspeed Venture Partners as their Swiss counsel. VISCHER advised ImmunOs. Walder Wyss advises Gimv. ImmunOs Therapeutics AG,...
You must be a Standard 1 Year member to access this content.
VISCHER advised Anaveon on the deal. Anaveon AG, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing led by incoming investor...
You must be a Standard 1 Year member to access this content.
Kellerhals Carrard advised Vifor Pharma on the transaction. Vischer advised Inositec on the deal. Vifor Pharma acquired the Swiss firm Inositec AG, a clinical stage biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
VISCHER AG advised Novaremed on the deal. Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through...
You must be a Standard 1 Year member to access this content.
VISCHER AG advises Polyphor AG on the deal. Walder Wyss advises Enbiotix Inc. on this transaction. Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late...
You must be a Standard 1 Year member to access this content.
VISCHER advised Combioxin SA on the deal. Combioxin SA, a clinical-stage biotechnology company based in Epalinges, Switzerland, entered into a worldwide licensing agreement with Eagle Pharmaceuticals,...
You must be a Standard 1 Year member to access this content.
